
|Articles|December 9, 2012
Elisabeth M. Paietta, PhD, Defines Minimum Residual Disease (MRD) and Discusses the Current Challenges of MRD Implementation
Elisabeth M. Paietta, PhD, Professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, defines minimum residual disease (MRD) and discusses its clinical significance. She then describes the methodological and therapeutic challenges that face clinical MRD implementation.
Advertisement
Elisabeth M. Paietta, PhD, Professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, defines minimum residual disease (MRD) and discusses its clinical significance. She then describes the methodological and therapeutic challenges that face clinical MRD implementation.
This video was taken on Sunday, December 9, at the American Society of Hematology's 54th Annual Meeting in Atlanta, GA.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Tozorakimab Curbs Multiple COPD Inflammatory Pathways, ERS Data Show
2
COPERNICOS Trial: Eosinophil-Guided ICS Reduction Safe in COPD, Vestbo Says
3
FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations
4
Primary Care Capacity Gaps Threaten Respiratory Prevention
5




